PDCD1 and cancer: We then performed a comprehensive pan-cancer analysis through The Cancer Genome Atlas (TCGA) (13) with the aim of uncovering potential biomarkers of clinical response to PD-1/PD-L1 blockade cancer immunotherapy, which may be helpful to improve the prediction accuracy in clinic.